CMI
REGN icon

Clare Market Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Clare Market Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-410
Closed -$286K – 164
2022
Q1 		$286K Buy
+410
New +$259K 0.09% 130

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Clare Market Investments's REGN Position: Q2 2022 in Review

Clare Market Investments sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 410 shares — an estimated $286K sold.

Clare Market Investments first reported a position in REGN in Q1 2022 and held it in 1 quarter. The position peaked at $286K in Q1 2022. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

  • Clare Market Investments reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Clare Market Investments sold 410 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $286K.
  • Clare Market Investments first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Clare Market Investments's Regeneron Pharmaceuticals position peaked at $286K in Q1 2022.
  • 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Clare Market Investments's 13F filing for Q2 2022, filed 20 Feb 2025.